Genfit: Q3 2025 Financial Information and Activities Update
Genfit reported third-quarter 2025 financials with cash and equivalents at €119.0 million and nine-month revenue of €39.2 million, driven...
Nanobiotix: Q3 2025 Update & 2026 Clinical Outlook
Nanobiotix has closed a non-dilutive royalty financing with HealthCare Royalty worth up to $71 million, delivering a $50 million...
Ocular Therapeutix Reports Inducement Grant Under NASDAQ Rule
Ocular Therapeutix has granted inducement equity awards to eight newly hired non-executive employees under its 2019 inducement stock incentive...
Novo Nordisk Finalizes Its Acquisition of Akero Therapeutics
Novo Nordisk has closed its acquisition of Akero Therapeutics for $54 per share in cash, valuing the deal at...
Sanofi’s Dupixent Approved for Children’s Asthma in Japan
Japan’s Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for children aged 6 to 11 with severe...
Amneal Announces FDA Approval For Prolia/Xgeva Biosimilars
FDA has approved two denosumab biosimilars from the Amneal–mAbxience partnership: Boncresa, referencing Prolia for osteoporosis and related uses, and...
Eurobio Scientific Announces Replacement of Statutory Auditor
Eurobio Scientific will ask shareholders on January 26, 2026 to approve the replacement of its statutory auditor, Endrix Lyo,...
Rectify, Boehringer Ingelheim Target Breakthrough CKD Care
Rectify Pharmaceuticals has signed a strategic research and licensing agreement with Boehringer Ingelheim to develop oral small molecules that...
Pluri & Remedy Cell Achieve Successful Clinical Manufacturing
Pluri has expanded its 2024 manufacturing agreement with Remedy Cell, confirming full technology transfer of Remedy Cell’s proprietary, cell-free...
Pacira Joins PROBE to Transform Osteoarthritis Research
Pacira BioSciences has joined PROBE, an IHI-funded public–private consortium aiming to redefine osteoarthritis research and care by building a...